Home » DEXCOM COMPLETES SERIES D PREFERRED STOCK FINANCING FOR $22.5 MILLION
DEXCOM COMPLETES SERIES D PREFERRED STOCK FINANCING FOR $22.5 MILLION
DexCom, a developer of sensors to continuously monitor glucose levels in people with diabetes, has completed a private Series D financing totaling $22.5 million. Warburg Pincus led the investment with previous Series A, B and C investors participating, including Canaan Partners, Federated Kaufmann Fund, Fog City Fund, RWI Group and St. Paul Venture Capital.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050104005861&newsLang=en)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct